Dr David Glover, a member of an industry task force set up to investigate how trials of this kind should be carried out in the future, told BBC Radio 4’s Today show, It may be that it was unpredicted by the tests that were done. I believe from the basic science it was predictable.”

Other experts, including monoclonal antibody pioneer rofessor Greg Winter, of the Laboratory of Molecular Biology in Cambridge, suggested that the drug’s developers may have been “lulled into a false sense of security” because the in vivo pre-clinical trials did not reveal anything to adverse in TGN1412 use.